Z
Zynerba Pharmaceuticals (Formerly AllTranz)
Pharmaceutical products via dermal solutions to treat a various neuroscience disorders
About Zynerba Pharmaceuticals (Formerly AllTranz)
Zynerba Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative transdermal CBD therapies for patients with rare and near-rare neuropsychiatric disorders. The company's primary product candidate, Zygel, is a CBD gel designed to be applied to the skin, offering a non-invasive treatment option for conditions such as Fragile X Syndrome, Autism Spectrum Disorder, and 22q11.2 Deletion Syndrome. Zynerba operates in the biopharmaceutical market, targeting unmet medical needs in niche patient populations. The business model revolves around advancing clinical trials, securing regulatory approvals, and ultimately commercializing their therapies. Revenue generation is anticipated through product sales, partnerships, and potential licensing agreements.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2023 | $200M | $200M | Harmony Biosciences | ↗ |
| IPO✓Exit | Aug 2015 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Zynerba Pharmaceuticals (Formerly AllTranz) is 330 monthly website visits, down 72.5% over the last three months. Zynerba Pharmaceuticals (Formerly AllTranz)'s team declined 67.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zynerba Pharmaceuticals (Formerly AllTranz) in the Easttown Township ecosystem
The Zynerba Pharmaceuticals (Formerly AllTranz) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
Harmony Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zynerba Pharmaceuticals (Formerly AllTranz) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zynerba Pharmaceuticals (Formerly AllTranz)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










